We are a national leader in improving technologies that treat heart rhythm disorders (arrhythmia), making them safer, more precise, and more successful. We have listed select trials below:

  • CABANA 

    The Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial (CABANA) has the overall goal of establishing the appropriate roles for medical and ablative intervention for atrial fibrillation. We are second in the world in enrollment.

  • AF Trial 

    Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients with Non-Valvular Atrial Fibrillation (AF Trial) will assess the effect of treatment called anticoagulation on the awareness, understanding, memory and intellectual capability of patients with irregular heartbeats.

    Anticoagulation is treatment with drugs that prevent the clotting of blood or strokes. This study will assess the effect of two FDA-approved drugs that prevent clotting of blood (dabigatran and warfarin) on the awareness, understanding, memory and intellectual capability of patients with irregular heartbeats.

  • Molecular Characteristics of Atrial Fibrillation in A Goat Animal Model

    This partnership with Utah State University Department of Animal, Dairy, and Veterinary Sciences will study spontaneous arrhythmias in a goat animal model. The study includes the effect of increased TGF-β1 protein expression on micro RNA involved in both structural and electrical remodeling of the atria of the heart that can increase susceptibility to atrial fibrillation.

  • LEADLESS II

    LEADLESS II is a prospective, non-randomized, single-arm, international multicenter, clinical safety and effectiveness trial of a leadless pacemaker system in patients who are indicated for a VVIR pacemaker. As part of this trial, we are the only center in the Intermountain region implanting leadless devices and the highest enrolling center in our region.